North Shore Hospital is a large public hospital in Takapuna, New Zealand, serving the northern part of Auckland. Located on Shakespeare Road near Lake Pupuke, it is administered by the Waitemata District Health Board, which provides health services to approximately 600,000 residents of the North Shore, Waitakere and Rodney districts of Auckland. Emergency Department staff at North Shore see more than 46,000 cases each year.
To compare perioperative, oncological, and survival outcomes of total gastrectomy (TG) versus subtotal gastrectomy (SG) in patients with locally advanced distal diffuse gastric adenocarcinoma treated with perioperative 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy. Diffuse distal gastric cancer is characterized by infiltrative growth patterns and early nodal metastasis. Whilst radical resection remains the cornerstone of curative treatment, the optimal extent of surgery with TG or SG, remains debated. This international multicenter cohort study analyzed data from patients with histologically confirmed diffuse gastric adenocarcinoma, located > 5 cm from the gastroesophageal junction. Endpoints included surgical margin status, nodal yield, perioperative morbidity, recurrence patterns, time-to-recurrence (TTR), and overall survival (OS). Outcomes were compared using multivariate analyses. In total, 188 (39.0
Noise (synonyms: variability, imprecision) in clinical data is underappreciated. All measurements are affected by noise and bias. Research studies enrol many patients to average out noise and use randomisation and double-blinding to counter bias. These mitigation techniques are often not available in clinical medicine, where individual patients typically have a variable measured only once. The example of echocardiographic assessment of aortic stenosis severity illustrates how the conventional presentation of data as point estimates masks wide variability in noise between variables, which affects utility. Adding aortic valve area to the quantification of aortic stenosis may result in poorer (noisier) estimates. Every clinical variable reported as a point estimate comes with an invisible cloud of uncertainty (noise) of varying size across variables. Being mindful of how this noise varies across variables should facilitate optimal clinical decisions.
BACKGROUND:Patient complaints provide a complementary lens on surgical safety, yet prior analyses have been small and specialty specific. We aimed to characterise themes, perioperative processes, system factors and outcomes in surgical complaints using a scalable, large language model (LLM)-assisted approach. METHODS:We performed a national, retrospective, cross-sectional, sequential methods study of publicly available investigation reports from the Aotearoa New Zealand Health and Disability Commissioner. All reports published since 1998 were retrieved and screened for relevance across all surgical specialties. A fixed-parameter LLM workflow extracted demographics, clinical context, complications, breached patient rights, system factors and outcomes. An inductive LLM-supported thematic synthesis generated complaint themes, followed by rescoring of theme relevance across reports. Human validation supported the LLM-assisted process (Cohen's κ >0.85). RESULTS:Of 1827 reports screened, 650 involved surgical care. Postoperative complications were frequent (84.2%), commonly accompanied by permanent disability (33.2%) or death (24.2%). Delays in recognition of deterioration (76.1%), escalation (58.3%) and definitive management (49.5%) of complications were common and associated with higher mortality. Prominent themes concerned postoperative clinical management/monitoring, communication/informed consent and professional conduct/competence. Technical/procedural errors and medication errors were comparatively less common. Breaches are most often related to reasonable care and skill, and to informed consent, with marked variation across specialties. CONCLUSIONS:Complaints about surgical care predominantly reflect postoperative monitoring, escalation and communication rather than intraoperative technical errors. System priorities should include robust deterioration recognition and response, reliable handover and escalation pathways, and strengthened consent and communication processes. An LLM-assisted pipeline can scale complaint analysis to support organisational learning and quality improvement.
BACKGROUND AND AIMS:Lipoprotein(a) [Lp(a)] is a causal contributor to atherosclerotic cardiovascular disease (ASCVD). While no therapies are currently approved solely for lowering Lp(a), subgroup analyses suggest that individuals with elevated Lp(a) may gain added benefit from intensive lipid-lowering strategies. No prior meta-analysis has compared evolocumab, alirocumab, inclisiran, lerodalcibep, and enlicitide in their Lp(a)-lowering efficacy. We aimed to determine whether proprotein convertase subtilisin/kexin type 9 (PCSK9) targeted therapies differ significantly in Lp(a) reduction, or whether agent selection can be guided primarily by other factors such as dosing frequency, cost, and patient preference. SOURCES OF MATERIAL:We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) reporting percent change in Lp(a) following treatment with the 5 PCSK9-targeted agents. A random-effects model calculated pooled estimates of percentage Lp(a) change, and mixed-effects meta-regression assessed differences between agents. ABSTRACT OF FINDINGS:Thirty-one RCTs were included. PCSK9 inhibitors and inclisiran reduced Lp(a) by a pooled mean of -25.76% vs control (95% CI -29.54 to -21.99; P < .0001). Meta-regression revealed no significant differences between agents (alirocumab vs evolocumab: +3.3%, 95% CI -1.40 to 8.07, P = .16; inclisiran vs evolocumab: +4.9%, 95% CI -2.31 to 12.16, P = .18; inclisiran vs alirocumab: +1.6%, 95% CI -5.38 to 8.55, P = .65). Lerodalcibep and enlicitide demonstrated similar approximate 25% reductions; however, insufficient trial numbers precluded a powered head-to-head comparison. CONCLUSIONS:No statistically significant differences in Lp(a) reduction were observed between currently available PCSK9-targeting medications. Agent selection may reasonably be based on non-efficacy factors, including administration frequency, cost, and patient preference.
BACKGROUND:Uncemented total knee arthroplasty (TKA) components were developed to improve fixation relative to cemented implants. While uncemented femoral components have yielded favorable results, outcomes for earlier uncemented tibial and patellar designs have been inconsistent. Contemporary trabecular-metal implants aim to enhance biological fixation by optimizing osseointegration, yet randomized data comparing fully uncemented constructs, including the patella, are limited. We conducted a prospective, single-blinded randomized controlled trial comparing 5-year radiological, clinical, and patient-reported outcomes of fully cemented and fully uncemented trabecular-metal TKA with patella resurfacing. METHODS:Between 2017 and 2020, 316 knees (280 patients) were randomized 1:1 to fully cemented (n = 158) or fully uncemented (n = 158) TKA with patella resurfacing. There were 15 patients randomized to the uncemented group who required cementation of at least one component. The primary outcome was implant fixation at five years, assessed on standardized radiographs for progressive and nonprogressive radiolucent lines. The secondary outcomes included revisions, other reoperations, and patient-reported outcome measures at five years. Risk ratios, t-tests, and Chi-square tests were performed using a modified intention-to-treat approach. RESULTS:Follow-up was 97% at five years. Uncemented TKA had fewer nonprogressive radiolucent lines than cemented TKA (two versus 27 cases, relative risk [RR]: 0.50, 95% confidence interval [CI]: 0.42 to 0.59, P < 0.001). There was one progressive radiolucency that occurred in the cemented group. There were no differences between the groups for revisions (one cemented versus two uncemented, RR 1.52, CI: 0.31 to 7.56, P = 0.55), other reoperations (10 cemented versus eight uncemented, RR: 0.90, CI 0.59 to 1.39, P = 0.66), or patient-reported outcome measures (Oxford Knee Score, EuroQol-5 Dimensions, International Knee Society Score, Pain Visual Analog Scale, Forgotten Joint Score, and Satisfaction). CONCLUSIONS:At five years, fully uncemented TKA using trabecular metal with patella resurfacing demonstrated equivalent clinical and patient-reported outcomes and similar revision/reoperation rates to fully cemented TKA, with fewer nonprogressive radiolucent lines. Longer-term follow-up is required to determine whether radiographic differences affect implant survivorship and longevity overall.